JT Pharma's Psychosis Pipeline

Psychosis: JT Pharma's antipsychotic lead, HPI 201, has dramatic antipsychotic properties in the key animal models of schizophrenia.

Key features of HPI201:

  • Works by a novel mechanism (as an antagonist of brain neurotensin receptors) versus current antipsychotics.
  • Does not produce negative symptoms associated with current antipsychotics (catalepsy induction, tolerance development, etc.).
  • Is orally bioavailable at a druggable dose.
  • Virtually all of the necessary preclinical studies (notably, long-term toxicology evaluations in two animal species) have been completed.

Current efforts: Preparation of IND for advancement to clinical trials.